First Time Loading...

TCR2 Therapeutics Inc
NASDAQ:TCRR

Watchlist Manager
TCR2 Therapeutics Inc Logo
TCR2 Therapeutics Inc
NASDAQ:TCRR
Watchlist
Price: 1.48 USD
Updated: May 8, 2024

Profitability Summary

TCR2 Therapeutics Inc's profitability score is 23/100. We take all the information about a company's profitability (such as its margins, capital efficiency, free cash flow generating ability, and more) and consolidate it into one single number - the profitability score. The higher the profitability score, the more profitable the company is.

23/100
Profitability
Score

We take all the information about a company's profitability (such as its margins, capital efficiency, free cash flow generating ability, and more) and consolidate it into one single number - the profitability score. The higher the profitability score, the more profitable the company is.

23/100
Profitability
Score
23/100
Profitability
Score

Past Growth

To be successful and remain in business, both growth and profitability are important and necessary. Net Income growth is often seen as a sign of a company's efficiency from an operational standpoint, but is influenced heavily by a company's goals and challenges and should therefore be assessed in conjunction with other metrics like revenue and operating income growth.

Margins

Profit margins represent what percentage of sales has turned into profits. Simply put, the percentage figure indicates how many cents of profit the company has generated for each dollar of sale.

Profit margins help investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Earnings Waterfall
TCR2 Therapeutics Inc

Revenue
0 USD
Operating Expenses
-131.4m USD
Operating Income
-131.4m USD
Other Expenses
-31.7m USD
Net Income
-163.1m USD

Margins Comparison
TCR2 Therapeutics Inc Competitors

Country Company Market Cap Operating
Margin
Net
Margin
US
TCR2 Therapeutics Inc
NASDAQ:TCRR
58.1m USD N/A N/A
US
Abbvie Inc
NYSE:ABBV
282.8B USD
30%
9%
US
Amgen Inc
NASDAQ:AMGN
163.1B USD
24%
13%
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
108.8B USD
39%
37%
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
105.5B USD
30%
29%
AU
CSL Ltd
ASX:CSL
135.1B AUD
26%
17%
US
Gilead Sciences Inc
NASDAQ:GILD
81B USD
32%
2%
US
Moderna Inc
NASDAQ:MRNA
46.5B USD
-100%
-116%
US
Seagen Inc
NASDAQ:SGEN
43.1B USD
-33%
-33%
US
Biogen Inc
NASDAQ:BIIB
32.1B USD
22%
12%
KR
Celltrion Inc
KRX:068270
40.3T KRW
30%
25%
Country US
Market Cap 58.1m USD
Operating Margin N/A
Net Margin N/A
Country US
Market Cap 282.8B USD
Operating Margin
30%
Net Margin
9%
Country US
Market Cap 163.1B USD
Operating Margin
24%
Net Margin
13%
Country US
Market Cap 108.8B USD
Operating Margin
39%
Net Margin
37%
Country US
Market Cap 105.5B USD
Operating Margin
30%
Net Margin
29%
Country AU
Market Cap 135.1B AUD
Operating Margin
26%
Net Margin
17%
Country US
Market Cap 81B USD
Operating Margin
32%
Net Margin
2%
Country US
Market Cap 46.5B USD
Operating Margin
-100%
Net Margin
-116%
Country US
Market Cap 43.1B USD
Operating Margin
-33%
Net Margin
-33%
Country US
Market Cap 32.1B USD
Operating Margin
22%
Net Margin
12%
Country KR
Market Cap 40.3T KRW
Operating Margin
30%
Net Margin
25%

Return on Capital

Return on capital ratios give a sense of how well a company is using its capital (equity, assets, capital employed, etc.) to generate profits (operating income, net income, etc.). In simple words, these ratios show how much income is generated for each dollar of capital invested.

Return on Capital Comparison
TCR2 Therapeutics Inc Competitors

Country Company Market Cap ROE ROA ROCE ROIC
US
TCR2 Therapeutics Inc
NASDAQ:TCRR
58.1m USD
-91%
-69%
-66%
-217%
US
Abbvie Inc
NYSE:ABBV
282.8B USD
35%
4%
16%
13%
US
Amgen Inc
NASDAQ:AMGN
163.1B USD
73%
4%
10%
9%
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
108.8B USD
23%
18%
22%
44%
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
105.5B USD
15%
12%
14%
17%
AU
CSL Ltd
ASX:CSL
135.1B AUD
15%
7%
11%
9%
US
Gilead Sciences Inc
NASDAQ:GILD
81B USD
3%
1%
18%
7%
US
Moderna Inc
NASDAQ:MRNA
46.5B USD
-38%
-29%
-29%
-56%
US
Seagen Inc
NASDAQ:SGEN
43.1B USD
-28%
-21%
-27%
-39%
US
Biogen Inc
NASDAQ:BIIB
32.1B USD
8%
5%
9%
8%
KR
Celltrion Inc
KRX:068270
40.3T KRW
5%
4%
6%
4%
Country US
Market Cap 58.1m USD
ROE
-91%
ROA
-69%
ROCE
-66%
ROIC
-217%
Country US
Market Cap 282.8B USD
ROE
35%
ROA
4%
ROCE
16%
ROIC
13%
Country US
Market Cap 163.1B USD
ROE
73%
ROA
4%
ROCE
10%
ROIC
9%
Country US
Market Cap 108.8B USD
ROE
23%
ROA
18%
ROCE
22%
ROIC
44%
Country US
Market Cap 105.5B USD
ROE
15%
ROA
12%
ROCE
14%
ROIC
17%
Country AU
Market Cap 135.1B AUD
ROE
15%
ROA
7%
ROCE
11%
ROIC
9%
Country US
Market Cap 81B USD
ROE
3%
ROA
1%
ROCE
18%
ROIC
7%
Country US
Market Cap 46.5B USD
ROE
-38%
ROA
-29%
ROCE
-29%
ROIC
-56%
Country US
Market Cap 43.1B USD
ROE
-28%
ROA
-21%
ROCE
-27%
ROIC
-39%
Country US
Market Cap 32.1B USD
ROE
8%
ROA
5%
ROCE
9%
ROIC
8%
Country KR
Market Cap 40.3T KRW
ROE
5%
ROA
4%
ROCE
6%
ROIC
4%

Free Cash Flow

Free cash flow (FCF) is the money a company has left over after paying its operating expenses and capital expenditures. The more free cash flow a company has, the more it can allocate to dividends, paying down debt, and growth opportunities.

If a company has a decreasing free cash flow, that is not necessarily bad if the company is investing in its growth.

See Also

Discover More